Osteotech Signs Agreement To Distribute Harvest Technologies' BMAC(...( EATONTOWN N.J. March 4 /- Osteote...),Health

EATONTOWN, N.J., March 4 /PRNewswire-FirstCall/ -- Osteotech, Inc. (Nasdaq: OSTE), a leader in the emerging field of biologic solutions for regenerative medicine, announced today that it has entered into a three-year agreement with Harvest Technologies Corporation to distribute the BMAC(TM) (Bone Marrow Aspirate Concentrate) System. Under the agreement, Osteotech has the exclusive right to distribute the BMAC(TM) System for bone regeneration in orthopedic and spinal surgical procedures in most of the United States.

Sam Owusu-Akyaw, Osteotech's President and Chief Executive Officer, stated, "Osteotech is very excited to partner with Harvest for the distribution of the BMAC(TM) System. We believe Harvest's proprietary BMAC(TM) System will complement Osteotech's proprietary technologies in Biocomposite, which includes the Plexur P(TM) and Plexur M(TM), and DBM, furthering Osteotech's regenerative healing equation - Matrix + Signal + Cell."

Mr. Owusu-Akyaw concluded, "We expect to begin to distribute the BMAC(TM) System before the end of the second quarter of 2008. We are currently putting the finishing touches on our roll-out plan and will begin training our sales team shortly. In conjunction with Harvest, we will introduce the BMAC(TM) System at the American Academy of Orthopedic Surgeons 2008 Annual Meeting, March 5 through 7, 2008, in San Francisco, California."

The BMAC(TM) System, developed and manufactured by Harvest, is the first "point-of-care" platform that makes possible the use of a clinically significant quantity of cellular compositions from a small aspirate of bone marrow. The BMAC(TM) System derives bone marrow aspirate concentrate, which is a rich source of autologous adult stem cells, in just 15 minutes.
'/>"/>